Laurus Labs is that rare pharma company which went from “Covid Hero” to “Margin Zero” and now back to “Growth Heroic.” The Q2 FY26 numbers are the stuff of comeback legends—Revenue ₹1,653 Cr ( +35 % YoY ), PAT ₹195 Cr (+883 % YoY ), and an EBITDA margin of 24 %, all while the stock has sprinted +108 % YoY like a biotech intern who just found out his paper got cited.
At ₹934, the market now values Laurus at ₹50,444 Cr, a tidy 73.8× P/E on an EPS of ₹12.7. Book value? ₹89. ROE? 7.4 %. Dividend yield? 0.13 %. So the stock’s basically whispering: “I’m not cheap, but I’ve got a pipeline.”
The Q2 showstopper was a margin upgrade and CDMO ramp-up that finally silenced the “ARV hangover” critics. But whether it’s sustainable or just a one-quarter placebo—we’ll audit that next.
2. Introduction – From ARV Hangover to CDMO Detox
In 2021, Laurus Labs was the darling of every small-cap fund manager and every retail WhatsApp group pharmacist. They supplied antiretrovirals (ARVs) globally, minted cash during Covid, and investors believed every fermentation tank was a gold mine.
Then 2022–23 happened: ARV pricing crashed, USFDA inspections brought anxiety, margins evaporated, and the stock halved faster than a paracetamol melts in hot tea.
But the company didn’t go into mourning—it went into mutation. Management pivoted from being “API-only” to becoming a multi-engine pharma platform: APIs + Finished Dosage + CDMO + Biotech. A corporate version of “multi-vitamin therapy.”
Cut to FY26: margins are recovering, synthesis (CDMO) is roaring, and the new R&D centre in Hyderabad looks more like a sci-fi lab than a cost centre. Investors are smiling again—but cautiously, like someone who’s just been told their medical reports are “mostly fine.”
3. Business Model – WTF Do They Even Do?
Laurus Labs now runs on four cylinders:
Generic APIs (46 % of 9M FY25 revenue) The OG business—manufacturing ARV, oncology, and cardio APIs. Once their cash cow, now a disciplined racehorse after ARV volatility. They still hold global leadership in third-party ARV APIs, but mix is shifting: ARVs 59 %, Onco 8 %, Other APIs 33 %.
Generics FDF (27 %) The formulations arm—think pills instead of powders. Growth +5 % YoY, aided by developed-market demand. Essentially, they’ve moved from “supplying ingredients” to “selling the finished dish.”
CDMO Synthesis (24 %) The glamour segment. Custom manufacturing for big pharma—70 + active projects, 10 already commercial, 20 + in animal health and crop protection. Segment revenue +33 % YoY; margins fat enough to make auditors emotional.
Biotechnology (3 %) Their “next-gen” moonshot via Laurus Bio—microbial fermentation, nutraceuticals, and even alternative proteins. Raised ₹120 Cr from Eight Roads & F-Prime, ₹40 Cr own top-up, building 400 KL fermentation capacity by FY27.
So yeah, from antiretroviral APIs to alternative meat proteins—talk about diversification.
4. Financials Overview
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue (₹ Cr)
1,653
1,224
1,570
+35.1 %
+5.3 %
EBITDA (₹ Cr)
403
178
382
+126 %
+5.5 %
PAT (₹ Cr)
195
20
162
+883 %
+20.4 %
EPS (₹)
3.61
0.37
3.02
+876 %
+19.5 %
Annualised EPS ≈ ₹14.4 → P/E ≈ 65×.
Auditor commentary: Profit grew nine-fold. That’s either operational excellence or Excel excellence—jury’s still out.
5. Valuation Discussion – Fair Value Range (For Education Only)
Method 1: P/E Approach
EPS ≈ ₹12.7 (TTM). Peers average ≈ 35–40×. → Fair Value Range = ₹445 – ₹510 × ( 12.7 × 35 to 40 ) = ₹445 – ₹510 per share (historic normal).
Method 2: EV/EBITDA
EV ₹52,592 Cr / EBITDA ₹1,491 Cr → EV/EBITDA ≈ 35×. Sector average ≈ 18–22×. → Educational Fair Value Range ≈ ₹480 – ₹600 per share.
Aug 2025: Board approved demerger of LSPL Unit-1 into Sriam Pharma and amalgamation of remaining LSPL into Laurus Labs—corporate jigsaw puzzle with April 2026 as appointed date.
Jul 2025: AP Govt allotted 531.77 acres for a ₹5,630 Cr pharma zone investment creating 6,350 jobs. CSR and capex had a baby.
Mar 2025: Acquired 26 % in Kurnool Renewables for ₹35 Cr — because green power is the new brown sugar.
Jan 2025: USFDA inspection — one observation only; management said “minor procedural,” investors heard “we survived.”
Question: Can a company spending ₹3,000 Cr on capex and ₹250 Cr on R&D still pretend to be mid-cap? Answer: Only if your auditors are philosophical.
